# Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

> **NCT07231250** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Li Zhiming** · enrollment: 40 (estimated)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma
- Chemo-free Therapy
- Bispecific Antibody

## Interventions

- **DRUG:** Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone

## Key facts

- **NCT ID:** NCT07231250
- **Lead sponsor:** Li Zhiming
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2026-09-15
- **Final completion:** 2028-09-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07231250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07231250, "Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07231250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*